It has been identified that insulin-like growth factor 1 (IGF-1) activated various pathways of the epithelial-mesenchymal transition (EMT) in a couple of tumors. At the same time, survivin is implicated in EMT of gastric cancer (GC). To date, the impact of survivin on IGF-1-mediated EMT of GC has not been featured. In this work, we used the immunohistochemistry and molecular and cellular experiments to investigate the existence and significance of IGF-1 and survivin. Our findings revealed that survivin protein can be observed in majority of samples in all GC samples. Importantly, survivin expression has an obvious association with GC stage, and metastasis. In vitro, GC cell line BGC823 was treated with different concentrations of IGF-1, resulting in the activation of p-ERK, p-AKT, survivin, and the expression of EMT biomarkers, including N-cadherin, MMP2, and Snail. However, the silencing of survivin eradicated the expression IGF-1-induced EMT biomarkers and affected the migration and invasion of BGC823 cells. In conclusion, IGF-1 signaling activated survivin expression and controlled the expression of EMT biomarkers in the development of GC. This study lays a new stage for the molecular therapy of GC patients in the clinical treatment.
IGF-1 Survivin EMT GC
This is a preview of subscription content, log in to check access.
We are thankful to the other members in our lab for their suggestions.
Conflicts of interest
Li B, Liu HY, Guo SH, et al. The postoperative clinical outcomes and safety of early enteral nutrition in operated gastric cancer patients. J BUON. 2015;20(2):468–72.CrossRefPubMedGoogle Scholar
Lyu X, Zheng D, Zhang H, et al. Hyperthermia improves immune function and radiotherapy efficacy in patients with post-operative recurrent gastric cancer. Hepatogastroenterology. 2014;61(136):2428–33.PubMedGoogle Scholar
Ryu MH, Yoo C, Kim JG, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015;51(4):482–8.CrossRefPubMedGoogle Scholar
Velho S, Fernandes MS, Leite M, et al. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol. 2014;20(44):16433–42.CrossRefPubMedPubMedCentralGoogle Scholar
Bartucci M, Morelli C, Mauro L, et al. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61(18):6747–54.PubMedGoogle Scholar
Lisztwan J, Pornon A, Chen B, et al. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res. 2008;10(4):R56.CrossRefPubMedPubMedCentralGoogle Scholar
Zhang Y, Moerkens M, Ramaiahgari S. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 2011;13(3):R52.CrossRefPubMedPubMedCentralGoogle Scholar
Li W, Chen YQ, Shen YB, et al. HIF-1α knockdown by miRNA decreases survivin expression and inhibits A549 cell growth in vitro and in vivo. Int J Mol Med. 2013;32(2):271–80.PubMedPubMedCentralGoogle Scholar
Du J, Li B, Fang Y, et al. Overexpression of class III β-tubulin, Sox2, and nuclear survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. BMC Cancer. 2015;15:536.CrossRefPubMedPubMedCentralGoogle Scholar
Peng Z, Wang CX, Fang EH, et al. Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J Gastroenterol. 2014;20(18):5403–10.CrossRefPubMedPubMedCentralGoogle Scholar
Katoh M. Epithelial-mesenchymal transition in gastric cancer (review). Int J Oncol. 2005;27(6):1677–83.PubMedGoogle Scholar
Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22(3):194–207.CrossRefPubMedGoogle Scholar
Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25(1):76–84.CrossRefPubMedGoogle Scholar
Liao YJ, Fang CC, Yen CH, et al. Niemann-pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: clinicopathological correlations and therapeutical implications. Int J Cancer. 2015;137(6):1341–51.CrossRefPubMedGoogle Scholar